LEXINGTON, Mass. and HEIDELBERG, Germany, Aug. 14 febitand the Translational Genomics Research Institute (TGen) today announced theformation of a collaboration in which TGen will evaluateNext-Generation-Sequencing equipment in conjunction with febit's proprietaryGeniom(R) Microarray Technology.
febit's HybSelect(TM) Technology enables selective DNA capture andelution, an extremely efficient method to preselect sequences forNext-Generation Sequencers. HybSelect is based on febit's proven GeniomTechnology and uses arrays within microfludic biochips for the selectionprocess of targeted DNA. Geniom biochips are programmable and can contain anydesired set of capture probes. The new method combines the extraordinaryperformance of latest sequencers with the efficient selection capabilities ofGeniom Technology.
"We are delighted to have TGen as our first U.S. pilot user of HybSelectwith the latest sequencing instrumentation," said Cord F. Staehler, presidentof febit. "We will obtain important data from TGen that will help us as weprepare for the official introduction of HybSelect in early 2009."The collaboration provides TGen scientists pre-market access to a highlydeveloped DNA capturing method.
"There's been a great deal of conversation on the future direction ofgenomic research centers on next generation sequencing," said MatthewHuentelman, Ph.D., TGen associate investigator and lead collaborator on thisproject. "This collaboration on the use and further development of thismethod enhances the opportunities for TGen researchers to make a difference inresearch utilizing next generation sequencing."
TGen has been a user of the Geniom One device for the production andmicroarray analysis of Geniom Biochips since 2006.
febit enables scientists to read, write and understand the code of life:DNA. With its unique Geniom technology and services, febit is the only companythat puts the control of simplified genomic research in the hand of the user.The seamless integration of DNA synthesis and analysis and the superiorsupport in experiment design and bioinformatics helps to understand data andturn it into results. febit's team of experienced scientists is dedicated tosupport customers to solve the challenge of understanding biologicalprocesses. Geniom is a technological and service platform successfullyimplemented in basic and applied research by renowned institutions andcompanies. Geniom exploits cutting-edge microarray technology for analysis andsynthesis of genes and genomes, providing superior time- and cost-efficiencycombined with an unsurpassed spectrum of applications.
The Translational Genomics Research Institute (TGen) is a non-profit501(c)(3) organization dedicated to conducting groundbreaking research withlife changing results. Research at TGen is focused on helping patients withdiseases such as cancer, neurological disorders and diabetes. TGen is on thecutting edge of translational research where investigators are able to unravelthe genetic components of common and complex diseases. Working withcollaborators in the scientific and medical communities, TGen believes it canmake a substantial contribution to the efficiency and effectiveness of thetranslational process. TGen's vision is of a world where an understanding ofgenomic variation can be rapidly translated in a manner tailored to individualpatients.www.tgen.org Contact: febit holding gmbh Russo Partners, LLC Eva Sterzel David Schull or Wendy Lau Public Relations Manager +1-212-845-4271 +49 (6221) 6510-300 [email protected]
mail to: [email protected] [email protected]